Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 3/20 | 0.77 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.77 |
| ▸ | LGALS4 | P56470 | 3/20 | 0.77 |
| ▸ | GJB2 | P29033 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | GBA1 | P04062 | 1/20 | 0.50 |
| ▸ | SELL | P14151 | 2/20 | 0.49 |
| ▸ | SELP | P16109 | 2/20 | 0.49 |
| ▸ | CETP | P11597 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15450956 | 1.00 | LGALS8 (0.77) | LGALS8LGALS3LGALS4GJB2MAPK1 | |
| SCHEMBL18685567 | 1.00 | LGALS8 (0.77) | LGALS8LGALS3LGALS4GJB2MAPK1 | |
| SCHEMBL12908202 | 1.00 | LGALS8 (0.77) | LGALS8LGALS3LGALS4GJB2MAPK1 | |
| SCHEMBL22067762 | 1.00 | LGALS8 (0.77) | LGALS8LGALS3LGALS4GJB2MAPK1 | |
| SCHEMBL25005884 | 1.00 | LGALS8 (0.77) | LGALS8LGALS3LGALS4GJB2MAPK1 | |
| SCHEMBL22067763 | 1.00 | LGALS8 (0.77) | LGALS8LGALS3LGALS4GJB2MAPK1 | |
| SCHEMBL23183598 | 1.00 | LGALS8 (0.77) | LGALS8LGALS3LGALS4GJB2MAPK1 | |
| SCHEMBL21068067 | 1.00 | LGALS8 (0.77) | LGALS8LGALS3LGALS4GJB2MAPK1 | |
| SCHEMBL23393554 | 1.00 | LGALS8 (0.77) | LGALS8LGALS3LGALS4GJB2MAPK1 | |
| SCHEMBL22431206 | 1.00 | LGALS8 (0.77) | LGALS8LGALS3LGALS4GJB2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 646 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388896-A1 | COMPOSITION AND METHODS FOR TRANSGENE INSERTION | CELYNTRA THERAPEUTICS SA (BE) | 2025-12-25 | — | — | US | claimed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | claimed |
| US-12383501-B2 | Production of salipro particles | Salipro Biotech AB (SE) | 2025-08-12 | — | — | US | claimed |
| WO-2025056467-A1 | POLYPHOSPHOESTER STABILIZING AGENTS, COMPOSITIONS, USES, AND MANUFACTURING METHODS THEREOF | GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULC (CA) | 2025-03-20 | — | — | WO | claimed |
| EP-4507722-A1 | NANOEMULSION UNIVERSAL INFLUENZA VACCINE | Bluewillow Biologics, Inc. (US) | 2025-02-19 | — | — | EP | claimed |
| EP-4486881-A1 | COMPOSITION AND METHODS FOR TRANSGENE INSERTION | Celyntra Therapeutics SA (BE) | 2025-01-08 | — | — | EP | claimed |
| CN-119137203-A | Photochromic element containing surfactant and method for producing same | 韩国技术教育大学校产学协力团 | 2024-12-13 | — | — | CN | claimed |
| CN-118717672-A | Sivelesta sodium nasal spray and preparation method thereof | 万特制药(海南)有限公司 | 2024-10-01 | — | — | CN | claimed |
| EP-4422607-A1 | ORAL AND NASAL COMPOSITIONS AND METHODS OF TREATMENT | Aquestive Therapeutics, Inc. (US) | 2024-09-04 | — | — | EP | claimed |
| US-12076397-B2 | Emulsion adjuvant for intramuscular, intradermal and subcutaneous administration | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-09-03 | — | — | US | claimed |
| CN-113412270-A | Alternative detergents for virus inactivation | 安进公司 | 2021-09-17 | — | — | CN | claimed |
| WO-2020190985-A1 | ALTERNATE DETERGENTS FOR VIRAL INACTIVATION | AMGEN INC. (US) | 2020-09-24 | — | — | WO | claimed |
| US-20200197494-A1 | PEPTIDE COMPOSITIONS AND METHODS OF USE | AEGIS THERAPEUTICS, LLC | 2020-06-25 | — | — | US | claimed |
| US-20180325994-A1 | ANTI-BACTERIAL COMPOSITIONS FOR DRUG ADMINISTRATION | AEGIS THERAPEUTICS, LLC | 2018-11-15 | — | — | US | claimed |
| US-20170189472-A1 | ANTI-BACTERIAL COMPOSITIONS FOR DRUG ADMINISTRATION | OPIANT PHARMACEUTICALS, INC. | 2017-07-06 | — | — | US | claimed |
| US-20160051624-A1 | ANTIBACTERIAL COMPOSITIONS FOR DRUG ADMINISTRATION | AEGIS THERAPEUTICS LLC (US) | 2016-02-25 | — | — | US | claimed |
| US-9114069-B2 | Antibacterial compositions for drug administration | AEGIS THERAPEUTICS, LLC (US) | 2015-08-25 | — | — | US | claimed |
| WO-2011014797-A1 | ANTIBACTERIAL COMPOSITIONS FOR DRUG ADMINISTRATION | AEGIS THERAPEUTICS, LLC (US) | 2011-02-03 | — | — | WO | claimed |
| US-20100068209-A1 | ANTIBACTERIAL COMPOSITIONS FOR DRUG ADMINISTRATION | Aegis Therapeuttics LLC (US) | 2010-03-18 | — | — | US | claimed |
| US-20060046969-A1 | Antibacterial compositions for drug administration | AEGIS THERAPEUTICS LLC (US) | 2006-03-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200197494-A1 | PEPTIDE COMPOSITIONS AND METHODS OF USE | IAPP, NGLY1, VIP | LGALS8 42/4885LGALS3 49/4885LGALS4 101/4885 |
| US-20250388896-A1 | COMPOSITION AND METHODS FOR TRANSGENE INSERTION | GDA, XPA, ERCC2 | LGALS8 968/4885LGALS3 242/4885LGALS4 628/4885 |
| US-12076397-B2 | Emulsion adjuvant for intramuscular, intradermal and subcutaneous administration | DBI, DLAT, ABHD5 | LGALS8 3881/4885LGALS3 3364/4885LGALS4 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.